ADG20

ADG20 is the half-life engineered version of ADG2, which is a neutralizing monoclonal antibody against SARS-CoV-2

Also Known As:

ADG-2 antibody; ADG-20; ADG2 antibody

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	COVID-19 06/01/2023 - "Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron."